Eikon Therapeutics is a clinical-stage biotechnology company headquartered in Hayward, California that integrates super-resolution fluorescence microscopy, automated single-molecule tracking (SMT), and machine learning to observe protein motion and interactions in live cells in real time. The proprietary high-throughput SMT platform powers genome-wide genetic screens and supports drug discovery programs across oncology, immunology, and neuroscience. Eikon's lead clinical candidates include BDB001 (a systemically administered TLR 7/8 co-agonist studied in advanced malignancies) and IMP1734 (a selective PARP1 inhibitor partnered with Impact Therapeutics). The company was founded in 2019 by Nobel laureate Eric Betzig and is led by CEO Roger Perlmutter, former president of Merck Research Laboratories. Eikon completed an upsized IPO on Nasdaq under the ticker EIKN in February 2026.
Eikon Therapeutics is publicly traded
IPO'd on February 5, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under EIKN.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2019
Employees
201–500
Total Funding
$1.12B
4 rounds
Last Private Valuation
$3.1B
February 26, 2025
Total raised $1.12B across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B
Date
January 6, 2022
Amount
$518M
Valuation
$3.1B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| February 26, 2025 | Series D | $350.7M | — | Not disclosed |
| June 1, 2023 | Series C | $106M | — | Not disclosed |
| January 6, 2022 | Series B | $518M | $3.1B | T. Rowe Price, CPP Investments, EcoR1 Capital |
Roger Perlmutter
Chief Executive Officer
Roy D. Baynes
Chief Medical Officer
Freddie Bowie
Chief Financial Officer
Michael Klobuchar
Chief Operating Officer
Benjamin Thorner
Chief Business Officer & General Counsel
Russ Berman
Chief Technology Officer
Barbara Howes
Chief People Officer
Eric Betzig
Co-Founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Recursion Pharmaceuticals
AI- and image-based drug discovery platform using high-throughput phenomics to identify therapeutics across oncology and rare disease.
Insitro
Machine-learning-driven drug discovery company combining cellular biology and ML to design therapeutics in oncology and other indications.
Relay Therapeutics
Precision oncology biotech leveraging protein motion and computational simulation (Dynamo platform) to develop small-molecule cancer drugs.
Schrodinger
Computational platform for physics-based drug design combined with internal pipeline in oncology and other therapeutic areas.
Genesis Therapeutics
AI-driven small-molecule drug discovery platform applying deep learning to molecular design for oncology and other diseases.
Isomorphic Labs
Alphabet-backed AI-first drug discovery company applying deep learning models (AlphaFold-derived) to design therapeutics.
Yes, Eikon Therapeutics is publicly traded under the ticker symbol EIKN on the Nasdaq. The company went public in February 5, 2026.
Eikon Therapeutics trades under the ticker symbol EIKN on the Nasdaq. It began trading in February 5, 2026.
Eikon Therapeutics (EIKN on the Nasdaq) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker EIKN to place an order.
Eikon Therapeutics went public in February 5, 2026 via ipo, with an offering valuation of approximately $3.1B. Eikon Therapeutics priced an upsized IPO of 21,177,600 shares at $18.00 per share on February 4, 2026, raising approximately $381 million in gross proceeds. Shares began trading on the Nasdaq Global Select Market under the ticker EIKN on February 5, 2026, opening at $17.05 (below the IPO price) and valuing the company at approximately $860 million at debut. J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho acted as joint book-running managers.
Eikon Therapeutics raised $1.12B across 4 disclosed funding rounds prior to its public listing.
Eikon Therapeutics was founded by Eric Betzig in 2019.
Eikon Therapeutics is headquartered in Hayward, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.